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Summary
Chronic airway infection and inﬂammation are key events in the clinical course of
cystic ﬁbrosis (CF). The most relevant, best investigated strain of bacteria in these
circumstances is Pseudomonas aeruginosa. Since pulmonary infection with P. aeruginosa
is localized in the lower conducting airways, treatment is accessible with the use of
inhaled aerosolized antibiotics. Tobramycin inhalation solution was the ﬁrst antibiotic
to be developed and approved (in 1998) for use as an aerosolized antibiotic in patients
with CF. The only other aerosolized antibiotic indicated for this use is aztreonam lysine
solution for inhalation, which has been approved by both European and US authorities.
In prospective, randomized, controlled trails, both agents exhibited a very acceptable
safety proﬁle, along with an increase in forced expiratory volume in 1 second and other
clinically relevant endpoints. New developments focus on such components as reducing the
treatment burden by using dry power inhalers, decreasing inhalation frequency to once
daily, penetrating P. aeruginosa bioﬁlms, and combining two antibiotics in one solution for
inhalation. However, the ideal aerosolized antibiotic regimen for the treatment of chronic
P. aeruginosa infection has yet not been selected.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Chronic airway inﬂammation and infection are the greatest
causes of morbidity and mortality in patients with cystic
ﬁbrosis (CF).1 Several different organisms have been
cultured from lower respiratory tract secretions, but the
most signiﬁcant and most-often-studied bacterial pathogen
associated with CF is Pseudomonas aeruginosa, which is
detected in about 50% of patients with the disease overall
and almost 80% of all adult patients.2 The initial infection
with Pseudomonas usually involves a planktonic, nonmucoid
strain, which may be followed by a variable period of
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intermittent or transient infection, in which the bacteria
are not detectable in every sputum culture. “Chronic”
infection can be deﬁned when more than 50% of the
cultures in the previous 12 months are positive3 and is
characterized by mucoid strains that form a structured
community of microbes in an exopolysaccharide matrix,
or bioﬁlm.4 Bioﬁlms protect bacteria both from the host
immune response and from antibiotics, since cells in bioﬁlms
are several times more resistant to antibiotics than are
those in the planktonic state.5 Antibiotics are typically used
for early, intermittent infection, with the goal being to
eradicate the pathogen. Once P. aeruginosa has established
itself in the respiratory tract of a person with CF, however,
eradication is rarely possible. Infection with chronic, mucoid
P. aeruginosa is associated with poorer growth, more rapid
decline in lung function, increased need for antibiotics
and hospitalization, and earlier mortality.6–11 Therefore,
effective antimicrobial therapies that suppress the growth
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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of this pathogen are useful in the management of individuals
with CF.
Although many other pathogens may also be present in
patients with CF, their role in the clinical course of the
disease is not as clear.12 Burkholderia cepacia complex can
cause a rapid deterioration in lung health,12 but since the
prevalence of these bacteria is so low, it is challenging
to design studies that would provide evidence on how
to treat infected patients. The prevalence of methicillin-
resistant Staphylococcus aureus (MRSA) is increasing in
the CF population,2 with evidence now demonstrating
that MRSA infection in CF is associated with declining
pulmonary function and increased mortality risk.13,14 As yet,
no consensus is available on treatment strategies for CF
patients with MRSA, although clinicians have begun to use
various eradication protocols and a randomized, controlled
trial is ongoing (clinicaltrials.gov identiﬁer NCT01349192).
Since most of the current evidence involves the use of
inhaled antibiotics for the treatment of P. aeruginosa
infection, that will be the focus of this paper.
The location of infection in patients with CF is
endobronchial – that is, in the large and small conducting
airways.15 Aerosol administration of antibiotics targets these
airways with high local drug concentrations, while limiting
systemic exposure and toxicity. Whereas inhaled antibiotics
have been studied for early eradication of microbes16,17
and are used by clinicians for pulmonary exacerbations,18
this discussion will focus on chronic suppressive treatment
of established infections for which the most evidence is
available.19 The goals of suppressive antibiotic therapy are
to reduce the bacterial density and inﬂammatory response,
and to prevent progressive lung injury. We will discuss the
available inhaled antimicrobials, as well as some of those in
clinical development, for the treatment of chronic airway
infection in persons with CF.
History of inhaled antibiotic use in CF
Although the use of aerosolized antibiotics to treat CF
dates back more than 50 years,20 with improvements in
nebulizer design, the use of these agents has become more
common. Since the early 1980s, there have been several
studies of inhaled antibiotics, including aminoglycosides,
beta-lactams, and polymyxins, for the treatment of CF.21
These studies had small sample sizes, varying subject
age and disease severity, different study designs and
treatment regimens, and used nebulizers with different
efﬁciencies. Since no approved formulations for inhalation
were available, drugs were compounded from intravenous
(IV) formulations containing preservatives, with doses
selected based on how parenteral formulations were
packaged, not by preclinical safety or efﬁcacy testing, or
by deﬁning a priori the amount of drug needed in the lower
airways. Despite these drawbacks, however, most of the
early studies showed beneﬁts in signs and symptoms of CF
lung disease, such as improving or preserving lung function,
clinical scores, and weight gain; or reducing pulmonary
exacerbations, hospitalizations, and P. aeruginosa sputum
density.21 Further, no serious safety issues were reported
with the use of inhaled antibiotics.
Many of the early studies included aerosolized to-
bramycin, which helped to answer some of the technical
issues related to delivery of antibiotics by inhalation. For
example, it was shown that aminoglycosides penetrate
poorly into the endobronchial space when administered
intravenously and that antimicrobial activity is inhibited
signiﬁcantly by the presence of sputum.22 Bench and phar-
macokinetic (PK) studies demonstrated that an ultrasonic
nebulizer delivered a large topical dose that could overcome
these barriers.23 Two studies showed that patients with
CF who inhaled 600mg of tobramycin from this device 3
times daily for up to 12 weeks experienced a peak in
the antimicrobial effect and improvement in lung function
after 2 to 4 weeks of treatment.24,25 Resistant strains of
P. aeruginosa emerged transiently in the 12-week study.24
These studies shaped the current treatment paradigm
of month-on, month-off therapy for chronic infection.
Subsequent in vitro26 and PK27,28 studies demonstrated that
the PARI LC® Plus Jet Nebulizer (PARI Respiratory Equipment
Inc., Midlothian, VA, USA) achieved equally high sputum
levels of tobramycin using a 300mg nominal dose. This
device and dose were then used in the phase 3 studies that
led to the approval of tobramycin inhalation solution (TIS).
Interestingly, no dose-ranging studies were conducted with
inhaled tobramycin prior to the approval of TIS.
Currently approved aerosol antibiotics
Tobramycin inhalation solution (TIS)
TIS (TOBI®, Novartis Pharmaceuticals, East Hanover, NJ,
USA) 300mg (60mg/mL) was approved by the US Food and
Drug Administration in 1998 for CF patients 6 years of
age with P. aeruginosa infection and a forced expiratory
volume in 1 second (FEV1) between 25% and 75% of predicted
values.29 The pivotal trials of more than 500 subjects with
CF demonstrated improved lung function and quality of
life, and reduced P. aeruginosa density and hospitalization
rates after 3 cycles of 28-days-on, 28-days-off therapy.30
The adolescent age-group exhibited the greatest FEV1
beneﬁt from TIS.31 In addition, subjects with resistant
strains of Pseudomonas (deﬁned by parenteral breakpoints)
experienced clinical beneﬁt with TIS, which indicates
that MIC breakpoints for resistance may be irrelevant
with inhaled tobramycin.31 Although large variability in
sputum levels was observed, almost all subjects had
peak sputum levels exceeding 10 times the minimum
inhibitory concentration (MIC) of their organism, and 95%
had concentrations exceeding 25 times the MIC.27 Systemic
exposure and incidence of side effects were low. A 72-week,
open-label extension study showed a continued FEV1 beneﬁt
of 4.7% above baseline in the original TIS group.32
In a subsequent study, subjects with milder lung disease
(FEV1 >75% predicted) experienced fewer exacerbations but
no signiﬁcant improvement in lung function after 3 TIS
cycles,33 emphasizing the difﬁculty in achieving certain
clinical endpoints as the health of the CF population
improves. The dosing frequency of TIS is twice daily by
jet nebulizer, which takes 15 to 20 minutes per treatment,
exclusive of equipment cleaning and disinfection. Attempts
to reduce this time burden are discussed in the article by
Geller and Madge in this supplement.34 One such effort
resulted in the approval of TIS as a 75mg/mL, 300mg
formulation (Bramitob®, Chiesi Farmaceutici S.p.A., Parma,
Italy) in 2003 in some European countries, which decreased
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the delivery time via the LC Plus nebulizer to about
12 minutes.35 Current treatment guidelines recommend the
use of TIS for CF patients 6 years of age with chronic
P. aeruginosa infection.36
Aztreonam lysine for inhalation solution (AZLI)
Aztreonam is a monobactam antibiotic that has been used
parenterally for the past 25 years to treat infections caused
by aerobic gram-negative bacteria, including P. aeruginosa.
It was reformulated as a lysine salt for inhalation delivery
via the PARI Altera® Nebulizer System. AZLI was recently
approved (Cayston®, Gilead Sciences, Foster City, CA, USA)
for CF patients with P. aeruginosa 7 years of age in the
United States37 and 18 years of age in the European
Union.38 Each 75mg dose takes only 2 to 3 minutes to
nebulize, but extra time is needed to reconstitute the
drug prior to each administration. The presence of sputum
does not interfere with bacterial killing of AZLI in vitro,
and inhalation of AZLI achieves variable but high sputum
concentrations that remain above the MIC of 90% of the
Pseudomonas strains for at least 4 hours.39 A dose-ranging,
placebo-controlled, phase 2 study in patients with FEV1
>40% predicted showed that the 75mg and 225mg AZLI
doses administered twice daily for 2 weeks signiﬁcantly
reduced bacterial density in sputum, but the lower dose
was associated with fewer adverse events.40 The endpoint
of FEV1 improvement was not met in this relatively healthy
group (mean FEV1 77% at baseline), but an exploratory
analysis demonstrated a better response in those with
lower lung function, as well as in those who routinely
used bronchodilators.40 Therefore, the subsequent phase 3
studies of AZLI included subjects with baseline FEV1 between
25% and 75% of predicted values, treatment was extended
to 4 weeks, and short-acting bronchodilators were used by
the participants prior to each dose.
A placebo-controlled, phase 3 study of AZLI administered 3
times daily demonstrated signiﬁcantly improved respiratory
symptom scores and lung function, reduced bacterial density
in sputum, and better weight gain in AZLI-treated subjects
vs. placebo-treated individuals over 4 weeks.41 There was
also a trend toward fewer hospitalizations in the AZLI group.
In another trial, groups of CF patients received AZLI 75mg
2 times daily or 3 times daily vs. placebo for 4 weeks,
after all groups had been treated with a 4-week run-in
period with TIS. Both AZLI groups experienced a longer time-
to-need for antipseudomonal antibiotics, improved FEV1,
improved respiratory symptoms, and lower sputum bacterial
density than the placebo group at the end of the 4-week
treatment period.42 In that study, no differences in beneﬁt
were noted between the treatment groups; however, an
open-label extension study (up to 9 month-on/month-off
cycles) showed that patients who remained on 3-times-daily
dosing in subsequent cycles experienced a better clinical
response, consistent with an antibiotic that demonstrates
time-dependent killing.43 Treatment response was observed
with AZLI regardless of age, baseline FEV1, or baseline
susceptibility of Pseudomonas to aztreonam. Of note, there
was no signiﬁcant change in the MIC of Pseudomonas
to aztreonam over the course of these studies, nor any
emergence of inherently resistant microbes.44
Since chronic P. aeruginosa infection affects many
CF patients with mild pulmonary involvement (FEV1
>75% predicted), it is important to recognize whether they
also derive a measureable beneﬁt from inhaled antibiotics.
Patients with mild lung impairment treated for 4 weeks with
AZLI 3 times daily (n = 76) did not demonstrate signiﬁcant
improvement in respiratory symptom scores vs the placebo
group (n = 81), but a modest, signiﬁcant 2.7% relative
improvement in FEV1 and reduced sputum bacterial density
in the AZLI group.45 Exploratory analyses showed that
subjects with an FEV1 <90% of predicted experienced more
signiﬁcant responses than did those with more normal lung
function, suggesting that the upper limit of lung function
may be raised above 75% to increase the pool of potential
subjects. AZLI is currently being investigated in open-label
studies of pediatric CF patients for eradication of early
Pseudomonas infection, as well as in those with chronic
infection.
Colistimethate sodium (colistin)
Colistimethate sodium (colistin; registered as Colomycin®,
Promixin® in the United Kingdom) is a polymyxin antibiotic
that has been used for many years mainly as inhalation
therapy for eradication46 and chronic suppression of Pseu-
domonas, but without any large, randomized, controlled
studies. The only placebo-controlled trial to be conducted
demonstrated a signiﬁcant difference in the rate of decline
of the forced vital capacity, but not FEV1, over the
90-day treatment period between colistin and placebo.47
A comparison study of colistin vs. TIS in patients with CF
(4-week treatment course) showed that both treatments
reduced P. aeruginosa sputum density, but only the TIS group
experienced a signiﬁcant improvement in FEV1 of 6.7%.48 The
study was conducted in the United Kingdom, where long-
term inhalation of colistin was common but use of TIS was
not, possibly favoring a response to TIS in a relatively naive
population. Furthermore, the dose of colistin used was only
half that commonly prescribed for adults.49
The Cystic Fibrosis Foundation Pulmonary Guidelines
Committee found insufﬁcient evidence to recommend for
or against the use of colistin for chronic P. aeruginosa
infection,36 but the agent was included in the European
guidelines on inhaled medications in CF.50 Colistimethate
sodium is often used on a continuous basis in chronically
infected patients. In countries where colistin is not
registered, many caregivers prescribe compounded, off-
label colistin for use in the “off” months of TIS cycles,
for patients with multi- or pan-resistant organisms, or for
those who cannot tolerate TIS.51 Use of IV formulations of
colistin for inhalation is associated with risks, however, as
exempliﬁed by the reported death of a CF patient who used
such a formulation.52
Aerosol antibiotics in clinical development
Although inhaled antibiotics have been in use for many
years, evidence still indicates that they are underutilized
among eligible patients.2,53 Many possible reasons for this
situation exist, including drug intolerance, the perception
that the antibiotic is no longer effective, and the high
cost and time burden associated with treatment. Adherence
to treatment is low, as described in an accompanying
paper.34 There is also the fear that overuse of the same
antimicrobials over time will place selective pressure on
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the CF microbiome, thus creating the emergence of bacteria
strains that are highly resistant to antibiotics. Having a panel
of inhaled agents from different antibiotic classes would
provide more treatment options and possibly reduce the
risk of selecting for bacterial resistance. Therefore, novel
formulations of aerosol antibiotics are being developed for
the treatment of CF, including polymyxins, aminoglycosides,
and ﬂuoroquinolones.
Polymyxins
A European randomized, double-blinded, phase 3 study54
of colistimethate sodium administered by a dry powder
inhaler (Colobreathe®, Forest Laboratories UK Ltd., London,
England) has been conducted, and recently received
authorization for approval from the European Medicines
Agency.
Aminoglycosides
Despite the registration of two TIS formulations, signiﬁcant
nonadherence to this agent exists, likely due to the
burden associated with drug administration (12 to 20
minutes twice daily) and nebulizer cleaning/disinfection.
Tobramycin inhalation powder (TIP), a light, porous-particle
formulation, was developed using PulmoSphere® (Inhalation
Therapeutic Systems, San Carlos, CA, USA) technology
to deliver tobramycin via a simple, capsule-based dry
powder inhaler.55 The delivery efﬁciency to the lungs is
about 3 times greater with TIP than with nebulized TIS,
with delivery of a 4-capsule, 112-mg dose taking only
5 minutes, without the need for device cleaning.56 The
phase 3 EVOLVE clinical trial, which was conducted in
a relatively undertreated CF population, demonstrated
signiﬁcant positive changes in pulmonary function, sputum
P. aeruginosa density, respiratory-related hospitalization,
and antipseudomonal antibiotic use in the TIP vs. placebo
groups.57 In the EAGER trial, TIP was compared with TIS over
three treatment cycles and was found to have comparable
efﬁcacy, but higher treatment satisfaction scores and a much
shorter administration time.58 In these studies, the main
side effect associated with the use of TIP was cough. TIP
was recently approved in Canada, Chile, and Europe (TOBI®
Podhaler®, Novartis Pharmaceuticals, Basel, Switzerland)
A liposomal formulation of amikacin is being developed for
inhalation via an investigational eFlow®59 device (Arikace®,
Insmed Incorporated, Monmouth Junction, NJ, USA).60 The
liposomes have been shown to penetrate bioﬁlms in vitro.61
Additionally, virulence factors secreted by P. aeruginosa
facilitate the release of amikacin from liposomes, thus
targeting the drug to the bacterial microenvironment.61
Whether this occurs in vivo is unclear, but the “Trojan horse”
concept of introducing antibiotics into a bioﬁlm is attractive.
Liposomes release drug over time, prolonging the residence
time in the airway and thus allowing longer dosing intervals.
As bacterial killing by such aminoglycosides as amikacin is
dependent on maximal concentration, not time dependent,
however, this prolonged residence time may not be the
factor that enhances the effectiveness of the antibiotic.
A European placebo-controlled study showed that 280-
mg and 560-mg once-daily doses of Arikace improved
FEV1 vs. placebo after 28 days, with a sustained effect
of the agent observed in the high-dose group. Fewer
hospitalizations were reported, and there was a longer time
before rescue antipseudomonal antibiotics were needed in
the Arikace groups.62 An open-label, continuation study of
Arikace 560mg once daily for up to 6 cycles (28 days on,
56 days off treatment) demonstrated continued clinical
beneﬁt with improved pulmonary function and decreased
sputum bacterial density that was sustained, even in the
off-treatment period.63 The pattern of MICs did not change
signiﬁcantly over the study period. Phase 3 studies are
planned for the future.
Fluoroquinolones
Fluoroquinolones administered via the oral and IV routes
have been used for years, exhibit activity against many
Gram-negative and Gram-positive bacteria (including S. au-
reus), and are currently being developed for inhalation use.
Two versions of inhaled ciproﬂoxacin are being investigated.
One formulation uses the same dry powder technology as TIP
(Bayer Healthcare AG, Leverkusen, Germany)64; a phase 2
study has been completed, (Clinicaltrials.gov identiﬁer
NCT00645788). A liposomal formulation of ciproﬂoxacin is
also being developed (Aradigm, Hayward, CA, USA) for
delivery via a jet nebulizer. In a small phase 2 study
in Australia and New Zealand, CF patients treated with
liposomal ciproﬂoxacin once daily for 2 weeks exhibited a
decrease in sputum P. aeruginosa density and an almost 7%
increase in FEV1 over baseline.65
Levoﬂoxacin (Aeroquin™ [MP-376], Mpex Pharmaceuticals,
San Diego, CA, USA) is being developed as a solution for
use with the investigational eFlow nebulizer. Levoﬂoxacin
has demonstrated effectiveness against P. aeruginosa and
other pathogens in the presence of sputum, anaerobic
environments, and even bioﬁlms, offering a theoretical
advantage over other antimicrobial agents.66,67 A recent
dose-ranging study showed that levoﬂoxacin 240mg twice
daily (high dose) was the most effective in a population
of heavily treated CF patients with chronic P. aeruginosa
infection and baseline FEV1 between 25% and 85% of
predicted.68 Results of this study showed a signiﬁcant
decrease in sputum P. aeruginosa density, the reduced
need for other antipseudomonal antibiotics, improved FEV1,
and a trend toward improved symptom scores at the end
of the 4-week treatment period.68 Bacterial density, lung
function, and symptom scores returned to baseline values
after 4 weeks off treatment. No correlation was observed
between clinical response and baseline MIC, nor was there
a signiﬁcant change in the MIC values for P. aeruginosa
over the course of the study. Treatment time was only 4
to 6 minutes per dose (not including the time needed for
device cleaning). Aeroquin is currently being studied in two
phase 3 clinical trials.
Fosfomycin
Fosfomycin is a phosphonic acid antibiotic with activity
against Gram-positive, Gram-negative, and anaerobic bac-
teria. The growing concern about MRSA in the CF population
has generated interest in exploring effective treatments for
organisms other than P. aeruginosa. Fosfomycin combined
with tobramycin in a 4:1 ratio (FTI, Gilead Sciences, Foster
City, CA, USA) is being developed for inhalation via the
eFlow nebulizer. In a recent multicenter trial, CF subjects
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with chronic P. aeruginosa and baseline FEV1 values between
25% and 75% of predicted were treated with a 4-week
course of AZLI, then randomized to placebo, low-dose, or
high-dose FTI administered twice daily for 4 weeks. All
groups exhibited clinical improvement after AZLI treatment,
but only the FTI groups maintained the beneﬁts, whereas
the placebo group returned to baseline values when off
treatment.69 P. aeruginosa density decreased signiﬁcantly
in the FTI groups, and colony counts were dramatically
reduced in those patients co-infected with S. aureus (both
methicillin-sensitive and methicillin-resistant strains). FTI
shows promise not only for the treatment of P. aeruginosa,
but also for the treatment of other pathogens detected in
the CF population.
Conclusion
Inhaled antibiotics have progressed from extemporaneous
or compounded drugs to carefully studied formulations.
They are now a mainstay in the treatment of chronic
airway infections in patients with CF. Since the approval of
TIS, most of the companies developing inhaled antibiotics
have tried to reduce the treatment burden associated with
the treatment of chronic infection. With more diverse
treatment choices available, however, clinicians will have
more questions to answer regarding which therapy to initiate
ﬁrst, how to make a selection among the available drugs,
and what chronic antibiotic regimen is best for their patients
with CF.
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